Filing Details

Accession Number:
0001213900-22-027797
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-17 21:57:14
Reporting Period:
2022-05-16
Accepted Time:
2022-05-17 21:57:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1733413 Tff Pharmaceuticals Inc. TFFP Pharmaceutical Preparations (2834) 824344737
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1789490 G.l. Aaron Fletcher 1751 River Run, Suite 400
Fort Worth TX 76107
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-05-16 85,000 $4.86 85,000 No 4 P Indirect See footnote
Common Stock Acquisiton 2022-05-17 24,600 $5.08 109,600 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 542,000 Indirect See footnote
Common Stock 100,000 Direct
Footnotes
  1. The reported shares were purchased in the open market in multiple transactions at prices ranging from $4.25 to $5.02. The price reported in Column 4 is a weighted average price.
  2. The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund II, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund II, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.
  3. The reported shares were purchased in the open market in multiple transactions at prices ranging from $4.80 to $5.18. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1) and (3).
  4. The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4